Alaunos Therapeutics, Inc.

NASDAQ (USD): Alaunos Therapeutics, Inc. (TCRT)

Last Price

2.40

Today's Change

-0.01 (0.41%)

Day's Change

2.40 - 2.86

Trading Volume

35,283

Overview

Market Cap

3 Million

Shares Outstanding

1 Million

Avg Volume

20,231

Avg Price (50 Days)

2.47

Avg Price (200 Days)

9.36

PE Ratio

-0.01

EPS

-319.97

Earnings Announcement

13-Nov-2024

Previous Close

2.41

Open

2.41

Day's Range

2.4 - 2.86

Year Range

1.95 - 33.0

Trading Volume

35,283

Price Change Highlight

1 Day Change

-0.41%

5 Day Change

18.81%

1 Month Change

13.74%

3 Month Change

-4.00%

6 Month Change

-81.10%

Ytd Change

-81.18%

1 Year Change

-80.75%

3 Year Change

-98.85%

5 Year Change

-99.65%

10 Year Change

-99.51%

Max Change

-99.90%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment